Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)

Professor Sergio Harari joins us to discuss the results of a
phase 2 clinical trial evaluating activity and safety of
nintedanib in people with lymphangioleiomyomatosis (LAM).


Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv